专题：Multiple Myeloma Research and Treatments

This cluster of papers focuses on the diagnosis, staging, treatment, and molecular classification of multiple myeloma. It covers topics such as the International Myeloma Working Group criteria, novel therapies including proteasome inhibitors and immunomodulatory drugs, autologous transplantation, genomic abnormalities, and the role of the bone marrow microenvironment in disease progression.
最新文献
Erratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study

erratum Full Text OpenAlex

Modification of Belantamab Mafodotin Dosing to Balance Efficacy and Tolerability in the DREAMM-7 and DREAMM-8 Trials

article Full Text OpenAlex

Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapy

article Full Text OpenAlex

Self‐Assembling Multi‐Antigen T Cell Hybridizers for Precision Immunotherapy of Multiple Myeloma

article Full Text OpenAlex

Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma

article Full Text OpenAlex

Venlafaxine-induced thrombocytopenia: A case report and literature review

review Full Text OpenAlex

Population Pharmacokinetic and Pharmacokinetic‐Pharmacodynamic Modeling of Serum M‐Protein Response for Modakafusp Alfa in a Phase 1/2 Study of Patients With Relapsed or Refractory Multiple Myeloma

article Full Text OpenAlex

Determinants of 15‐Year Progression‐Free Survival in Multiple Myeloma; Real‐World Data From a Single Institution

article Full Text OpenAlex

Elranatamab for Relapsed/Refractory Multiple Myeloma With Severe Renal Impairment Requiring Hemodialysis

article Full Text OpenAlex

Utility of IDH1/2 mutations as biomarkers for detection of measurable residual disease in acute myeloid leukemia

article Full Text OpenAlex

近5年高被引文献
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

article Full Text OpenAlex 2082 FWCI431.525

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

article Full Text OpenAlex 1892 FWCI164.588

Teclistamab in Relapsed or Refractory Multiple Myeloma

article Full Text OpenAlex 760 FWCI160.275

Diagnosis and Management of Multiple Myeloma

review Full Text OpenAlex 710 FWCI42.119

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

article Full Text OpenAlex 669 FWCI96.67

Multiple myeloma

review Full Text OpenAlex 637 FWCI27.056

Multiple myeloma: 2022 update on diagnosis, risk stratification, and management

article Full Text OpenAlex 636 FWCI125.275

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

article Full Text OpenAlex 480 FWCI184.887

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

article Full Text OpenAlex 460 FWCI64.125

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

article Full Text OpenAlex 442 FWCI170.002